Results 41 to 50 of about 51,827 (228)
Current Status and Future Prospect of Medical Radioisotopes Production in China
He huaxue yu fangshe huaxueThis study examines the current state of medical radioisotope production in China. It aims to evaluate production technologies, industrial applications, and clinical impacts of diagnostic and therapeutic radioisotopes.
Kai WEN +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner +5 more
wiley +1 more source
Journal of Interventional Epidemiology and Public HealthIntroduction: L’approche World Health Organization Package of Essential Nonconmmunicable (WHOPEN)permet la prévention, la détection précoce et la prise en charge de l’hypertension artérielle (HTA) et diabète.
Bassotom Lakougnon +9 more
doaj +1 more source
Journal of Pharmaceutical Policy and Practice, 2021 Background Advanced therapy medicinal products (ATMPs) represent an important cornerstone for innovation in healthcare. However, uncertainty on the value, the high average cost per patient and their one-shot nature has raised a debate on their assessment
Virginia Ronco +4 more
doaj +1 more source
, 2010 L’approccio tradizionale di HTA, che include una revisione sistematica della letteratura, una valutazione economica, un’analisi di impatto di budget, fornisce un utile scenario evidence-based per prendere decisioni.
VENTURINI, FRANCESCA
core +1 more source
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
Journal of Market Access & Health Policy, 2019 Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines.
Oriol Solà-Morales +2 more
doaj +1 more source
Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA; Comment on “Ethics in HTA: Examining the ‘Need for Expansion’” [PDF]
International Journal of Health Policy and Management, 2019 Abrishami, Oortwijn, and Hofman (AOH) attribute to me a position I do not hold and an argument I did not make. The purpose of this note is make clear what my position actually is and to clarify the main differences between health technology assessment ...
Anthony J. Culyer
doaj +1 more source
KESELAMATAN KERJA PADA BONGKAR MUAT KAPAL MINI PURSE SEINE 10 GT DI PELABUHAN PERIKANAN LEMPASING
Jurnal Teknologi Perikanan dan Kelautan, 2023 Pelabuhan Perikanan Pantai (PPP) Lempasing merupakan pelabuhan perikanan terbesar di Lampung. Salah satu kapal yang paling banyak dioperasikan di Pelabuhan Lempasing yaitu mini purse seine.
Lilis Nurbaiti +2 more
doaj +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source